STOCK TITAN

Grace Therapeutics: ADAR1 reports 9.9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) is the issuer in an amended beneficial-ownership report from ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC and Daniel Schneeberger. ADAR1 Capital Management and Mr. Schneeberger each report 2,281,877 shares, or 9.9%, with shared voting and dispositive power; these are overlapping attributions, not separate holdings to add. The reported amount includes 414,285 common shares held by ADAR1 Partners, LP, 61,905 held by Spearhead Insurance Solutions IDF, LLC and 1,805,687 shares underlying prefunded and milestone warrants. ADAR1 Capital Management GP reports 1,940,042 shares, or 8.6%, including 414,285 shares held by ADAR1 Partners and 1,525,757 shares underlying warrants. The report excludes 69,860 additional warrant shares subject to 9.99% beneficial ownership limitations.

Beneficial ownership 2,281,877 shares Reported by ADAR1 Capital Management, LLC and Daniel Schneeberger, with shared voting and dispositive power
Beneficial ownership percentage 9.9% Reported by ADAR1 Capital Management, LLC and Daniel Schneeberger
Beneficial ownership 1,940,042 shares Reported by ADAR1 Capital Management GP, LLC
Beneficial ownership percentage 8.6% Reported by ADAR1 Capital Management GP, LLC
Shares underlying warrants included 1,805,687 shares Prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC
Shares underlying warrants included 1,525,757 shares Prefunded and milestone warrants held by ADAR1 Partners, LP
Warrant shares excluded 69,860 shares Exchange and exercise are subject to 9.99% beneficial ownership limitations
Common shares outstanding 21,035,930 shares Cited by ADAR1 Capital Management, LLC as of September 30, 2026
beneficial ownership limitations regulatory
"exchange and exercise are subject to 9.99% beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
prefunded warrants financial
"shares of Common Stock underlying prefunded and milestone warrants"
Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.
milestone warrants financial
"shares of Common Stock underlying prefunded and milestone warrants"
Milestone warrants are rights that let holders buy a company’s stock only if specific goals—such as regulatory approvals, sales targets, or project completions—are met. Think of them as a coupon that only becomes usable when the company hits agreed checkpoints; they matter to investors because they create contingent value and potential share dilution, and they signal which outcomes the company and its backers consider most important.
shared voting power regulatory
"Shared Voting Power 2,281,877.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared Dispositive Power 2,281,877.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GRCE shares does ADAR1 Capital Management report beneficially owning?

ADAR1 Capital Management, LLC reports 2,281,877 shares, or 9.9%, with shared voting and dispositive power. Daniel Schneeberger reports the same amount through indirect beneficial ownership; these are overlapping attributions, not additive positions.

How many GRCE shares does ADAR1 Capital Management GP report?

ADAR1 Capital Management GP, LLC reports 1,940,042 shares, or 8.6%. This includes 414,285 shares held by ADAR1 Partners, LP and 1,525,757 shares underlying prefunded and milestone warrants held by that partnership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





00439U104

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 414,285 shares of common stock, par value $0.0001 per share ("Common Stock"), held by ADAR1 Partners, LP, (ii) 61,905 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,805,687 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of September 30, 2026. Excludes 69,860 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 21,035,930 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of September 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 414,285 shares of Common Stock held by ADAR1 Partners, LP and (ii) 1,525,757 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP as of September 30, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 21,035,930 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of September 30, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 414,285 shares of common stock, par value $0.0001 per share ("Common Stock"), held by ADAR1 Partners, LP, (ii) 61,905 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,805,687 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of September 30, 2026. Excludes 69,860 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 21,035,930 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of August 11, 2026, reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 13, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
ADAR1 Capital Management GP, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026

Keep reading